IPAB revokes patents on two drugs of Allergan

The Intellectual Property Apellate Board has revoked patents of two drugs of US-based speciality pharmaceutical company Allergan Inc used for eye treatments.
The patent on drugs Ganfort and Combigan, prescribed for eye-related treatment, has been revoked on a petition filed by Ajantha Pharmaceuticals.
"The revocation of the patent was sought on various grounds that the patent was obtained on a false suggestion or representation, that it is not an invention that it is obvious and does not sufficiently disclose and that the Section 8 of the Patents Act, 1970 was violated", IPAB said in its order delivered yesterday.
IPAB order said the "respondents (Allergan Inc) have incorrectly deciphered enhancement in therapeutic efficacy as 'reduction in interocular pressure comparable to serial application".

The respondent has not shown that it had complied with the Section 8 of Patents Act, 1970. For the above reasons, the patent deserves to be revoked, it said.
Recently, IPAB had revoked patents on Bangalore based Pfizer Inc's cancer drug Sutent.